Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. by Magee, LA et al.
AOGS ORIGINAL RESEARCH ARTICLE
Can adverse maternal and perinatal outcomes be predicted
when blood pressure becomes elevated? Secondary analyses
from the CHIPS (Control of Hypertension In Pregnancy Study)
randomized controlled trial
LAURA A. MAGEE1,2,3,4,*, PETER VON DADELSZEN1,2,3,4, JOEL SINGER3,5, TERRY LEE6, EVELYNE REY7,
SUSAN ROSS8, ELIZABETH ASZTALOS9,10,11, KELLIE E. MURPHY10,11, JENNIFER MENZIES3,
JOHANNA SANCHEZ11, AMIRAM GAFNI12, ANDREE GRUSLIN13, MICHAEL HELEWA14,
EILEEN HUTTON15, SHOO K. LEE9, ALEXANDER G. LOGAN16, WESSEL GANZEVOORT17,
ROSS WELCH18, JIM G. THORNTON19 & JEAN MARIE MOUTQUIN20
1St. George’s University of London, London, 2St. George’s University Hospitals NHS Trust, London, UK, 3Obstetrics and
Gynaecology, University of British Columbia, Vancouver, British Columbia, 4Child and Family Research Institute, University
of British Columbia, Vancouver, British Columbia, 5School of Population and Public Health, University of British Columbia,
Vancouver, British Columbia, 6Centre for Health Evaluation and Outcome Sciences (CH_EOS), Providence Health Care
Research Institute, University of British Columbia, Vancouver, British Columbia, 7Medicine and Obstetrics and Gynaecol-
ogy, University of Montreal, Montreal, Quebec, 8Obstetrics and Gynaecology, University of Alberta, Edmonton, Alberta,
9Pediatrics, University of Toronto, Toronto, Ontario, 10Obstetrics and Gynaecology, University of Toronto, Toronto,
Ontario, 11The Centre for Mother, Infant and Child Research, Sunnybrook Research Institute, University of Toronto,
Toronto, Ontario, 12Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, 13Obstetrics and
Gynaecology, University of Ottawa, Ottawa, Ontario, 14Obstetrics and Gynaecology, University of Manitoba, Winnipeg,
Manitoba, 15Obstetrics and Gynaecology, McMaster University, Hamilton, Ontario, 16Medicine, University of Toronto,
Toronto, Ontario, Canada, 17Obstetrics and Gynaecology, University of Amsterdam, Amsterdam, the Netherlands,
18Obstetrics and Gynaecology, Derriford Hospital, Plymouth, 19Obstetrics and Gynaecology, University of Nottingham,
Nottingham, UK, and 20Obstetrics and Gynaecology, Sherbrooke University, Sherbrooke, Quebec, Canada
Key words
Preexisting hypertension, chronic
hypertension, gestational hypertension,
prediction, adverse outcome, maternal,
perinatal
Correspondence
Laura A. Magee, Department of
Cardiovascular and Cell Sciences, St George’s,
University of London, Cranmer Terrace,
London SW17 0RE, UK.
E-mail: lmagee@sgul.ac.uk
Conflict of interest
Dr. von Dadelszen receives consultancy fees
and placental growth factor (PlGF) cartridges
for research from Alere International. The
other authors have stated explicitly that there
are no conflicts of interest in connection with
this article.
*For the CHIPS Study Group (see Table S1).
Please cite this article as: Magee LA, von
Dadelszen P, Singer J, Lee T, Rey E, Ross S,
Abstract
Introduction. For women with chronic or gestational hypertension in CHIPS
(Control of Hypertension In Pregnancy Study, NCT01192412), we aimed to
examine whether clinical predictors collected at randomization could predict
adverse outcomes. Material and methods. This was a planned, secondary analysis
of data from the 987 women in the CHIPS Trial. Logistic regression was used to
examine the impact of 19 candidate predictors on the probability of adverse peri-
natal (pregnancy loss or high level neonatal care for >48 h, or birthweight <10th
percentile) or maternal outcomes (severe hypertension, preeclampsia, or delivery
at <34 or <37 weeks). A model containing all candidate predictors was used to
start the stepwise regression process based on goodness of fit as measured by the
Akaike information criterion. For face validity, these variables were forced into
the model: treatment group (“less tight” or “tight” control), antihypertensive
type at randomization, and blood pressure within 1 week before randomization.
Continuous variables were represented continuously or dichotomized based on
the smaller p-value in univariate analyses. An area-under-the-receiver-operating-
curve (AUC ROC) of ≥0.70 was taken to reflect a potentially useful model. Result-
s. Point estimates for AUC ROC were <0.70 for all but severe hypertension (0.70,
95% CI 0.67–0.74) and delivery at <34 weeks (0.71, 95% CI 0.66–0.75). There-
fore, no model warranted further assessment of performance. Conclu-
sions. CHIPS data suggest that when women with chronic hypertension develop
an elevated blood pressure in pregnancy, or formerly normotensive women
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develop new gestational hypertension, maternal and current pregnancy clinical
characteristics cannot predict adverse outcomes in the index pregnancy.
Abbreviations: ART, artificial reproductive technology; AUC ROC, area under
the receiver-operating-characteristic; BMI, body mass index; BP, blood pressure;
dBP, diastolic blood pressure; HDP, hypertensive disorder of pregnancy; OR,
odds ratio; PNV, prenatal vitamin; sBP, systolic blood pressure.
Introduction
The hypertensive disorders of pregnancy (HDPs) are a lead-
ing cause of maternal and perinatal mortality and morbidity
worldwide. Preeclampsia is the HDP associated with the
greatest risk. As such, there is a large literature devoted to
the study of the prediction of preeclampsia in different
patient populations and at various time points in preg-
nancy. To date, no model has demonstrated sufficient accu-
racy to be applied in clinical practice. Under active study are
multivariable approaches that combine clinical information,
ultrasonographic results, and/or biomarker levels (1,2).
Ascertaining prognosis once a HDP has developed has
been less well-studied. The published literature focuses on
preeclampsia. Among such women, those with a heightened
risk of adverse maternal outcome can be identified up to
1 week following admission to hospital in well and under-
resourced settings using maternal demographics, symptoms,
signs, and standard maternal laboratory and fetal ultrasono-
graphic testing (3,4). The added value of angiogenic mark-
ers has also been demonstrated for timing delivery (5,6).
Is it possible to predict adverse outcomes among women
with chronic or gestational hypertension? Individual risk
markers for adverse outcomes have been identified, for out-
comes that include preeclampsia, preterm birth, severe
hypertension, and birthweight <10th centile. However,
there are no robust multivariable models. Among women
with a history of chronic hypertension who become hyper-
tensive in pregnancy, risk markers for adverse outcomes
have not been studied; when pregnant women were identi-
fied as hypertensive prior to pregnancy (whether or not they
had become hypertensive in pregnancy), markers for
adverse outcomes later in pregnancy have included dura-
tion of hypertension of 4 years or more and preeclampsia
in a prior pregnancy (for prediction of preeclampsia), as
well as baseline proteinuria (for prediction of preterm
delivery and birthweight <10th percentile) (7). Among
women with gestational hypertension, risk markers for
adverse outcomes (including preeclampsia, delivery at
<34 weeks, severe hypertension, and birthweight <10th
percentile) have included: gestational age <32 weeks at pre-
sentation with hypertension, severe hypertension, and
higher blood pressure (BP) and serum uric acid; however,
even when gestational age-standardized values were used
for BP and uric acid, the likelihood ratios for prediction of
adverse outcomes were poor at best (8,9).
In the CHIPS (Control of Hypertension In Pregnancy
Study) international randomized trial, 987 women were
allocated to a target diastolic BP (dBP) of 100 mmHg
(“less tight” control) or 85 mmHg (“tight” control) (10).
“Tight” control was of benefit to the mother (at mini-
mum, by decreasing the incidence of severe hyperten-
sion), without increasing (or decreasing) risk to the baby.
We sought to examine, for women with chronic or gesta-
tional hypertension enrolled in CHIPS, whether major
adverse outcomes could be predicted by clinical charac-
teristics at the time women were hypertensive and eligible
to join the Trial. Our hypothesis was that predictors of
adverse outcome may be more powerful at this point in
time for women with chronic hypertension who made up
approximately 75% of the CHIPS cohort.
Material and methods
In brief, CHIPS was an open pragmatic international
multicenter trial (ISRCTN 71416914, NCT01192412,
http://pre-empt.cfri.ca/CHIPS) approved by the Research
Ethics Board at the University of British Columbia as the
Co-ordinating Centre (H08-00882) and at all study sites.
Women at 14+0 to 33+6 weeks’ gestation with non-
proteinuric preexisting or gestational hypertension, ele-
vated BP (office dBP 90–105 mmHg, or 85–105 mmHg if
Key Message
CHIPS data suggest that it is not possible to predict
adverse maternal or perinatal outcomes in pregnancy
at the time that a woman becomes hypertensive in
that pregnancy.
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on antihypertensives), and a live fetus were randomized
(centrally and stratified by center and hypertension type)
to “less tight” (target dBP 100 mmHg) or “tight” control
(target dBP 85 mmHg) (10). Women could be recruited
on an antihypertensive agent (other than atenolol from
≥14+0 weeks’ gestation). Post-randomization, labetalol
was the recommended antihypertensive of first choice.
Candidate predictors
The 19 candidate predictor variables were measured at
baseline to determine eligibility and to document status at
randomization. These were variables either demonstrated
to increase maternal and/or perinatal risk in prior studies
(11–13), as follows: treatment group (“less tight” or “tight”
control), maternal age (years, continuously and as <35/
≥35), mother’s self-declared ethnicity (Caucasian/Asian/
other or Black/Hispanic), body mass index (BMI) (kg/m2,
continuously and as unknown/<25/≥25), conceived
through use of artificial reproductive technology (ART),
gestational age at randomization (weeks, continuously and
as <20/≥20), nulliparity, type of hypertension (preexisting/
gestational), prior severe hypertension in this pregnancy,
antihypertensive therapy at randomization, type of antihy-
pertensive therapy at randomization (none/labetalol with
or without another antihypertensive other than methyl-
dopa/methyldopa with or without another antihyperten-
sive other than labetalol/other), systolic BP (mmHg)
within 1 week before randomization (mmHg, continu-
ously and as <140/140–149/≥150), dBP within 1 week
before randomization (mmHg, continuously and as <90/
90–94/95–99/≥100), in hospital at enrolment, gestational
diabetes at randomization, cigarette smoking during this
pregnancy, aspirin at enrolment, folic acid and/or a prena-
tal vitamin (PNV) at enrolment, perinatal mortality ratio
of recruiting country (low defined as <10/1000 births or
high defined as ≥10/1000 births). As these variables were
collected prior to randomization, none was concealed from
the attending clinicians and all variables were known prior
to any post-randomization adverse outcomes. No serum
or urinary biomarkers were collected in CHIPS.
Outcomes
The composite primary outcome in CHIPS was preg-
nancy loss or high level neonatal care (greater than nor-
mal newborn care) for >48 h in the first 28 days of life.
The composite secondary outcome in CHIPS was serious
maternal complications before 6 weeks postpartum or
until hospital discharge, whichever was later. Serious
maternal complications included death, stroke, eclampsia,
blindness, uncontrolled hypertension, the use of inotropic
agents, pulmonary edema, respiratory failure, myocardial
ischemia or infarction, hepatic dysfunction, hepatic hema-
toma or rupture, renal failure, and transfusion. Additional
outcomes were severe hypertension, birthweight <10th
percentile, and preterm delivery at <34 or <37 weeks.
Further details can be found in the CHIPS protocol
(http://pre-empt.cfri.ca/CHIPS), the main CHIPS publica-
tion (10) and Table S2.
Sample size
This was a secondary analysis of an existing trial data set.
Based on the trial size of 987 women and adverse out-
comes rates of 14.1–47.3%, our 19 candidate predictor
variables could be considered according to the recom-
mendation of a minimum of five to 10 events per variable
(14). With only 28 (2.9%) secondary maternal outcomes
and 22 (2.2%) abruptions, these outcomes were not con-
sidered for predictive modeling.
Statistical analyses
Candidate predictors were compared between women
with an adverse outcome and those without, using the
Chi-squared test, Fisher’s exact test or Wilcoxon rank
sum test as appropriate.
Logistic regression was used to examine the impact of
each candidate predictor on the probability of each out-
come. A stepwise regression technique based on goodness
of fit (as measured by the Akaike information criterion)
was used to determine the subset of covariates most pre-
dictive of each outcome. A model containing the 19 can-
didate variables was used to start stepwise regression.
These variables were forced into the model regardless of
their impact on the model goodness of fit: treatment
group (“less tight” or “tight” control), type of antihyper-
tensive therapy at randomization (labetalol, methyldopa,
“other” or “none”), and both systolic BP (sBP) and dBP
within 1 week before randomization (continuous vari-
able). For variables that could be expressed as both con-
tinuous and dichotomous, we used the representation of
the variable that had the smaller p-value in univariable
analyses. An odds ratio (OR) >1 suggested a higher odds
of experiencing the outcome. In a sensitivity analysis, for
each outcome, we examined whether there was an inter-
action between antihypertensive therapy at enrolment (as
yes or no) and any variables in the final model.
For each outcome, the final model was evaluated
based on discrimination ability using the area-
under-the-receiver-operating-characteristic (AUC ROC)
curve; an AUC ROC ≥0.70 was considered evidence of
good discrimination (15). The model or models with
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good discrimination were to be assessed for calibration,
stratification capacity, predictive performance, and inter-
nal validity (16).
All statistical analyses were performed using SAS 9.4
(SAS Institute Inc., Cary, NC, USA) and R 3.2.0 (R
Development Core Team, Vienna, Austria).
Table 1. Baseline maternal characteristics considered as candidate predictors for the occurrence of adverse perinatal outcomes [n (%) unless
otherwise specified].
Variable
Primary outcomea
pb
Birthweight <10th percentile
pbNo (n = 676) Yes (n = 305) No (n = 801) Yes (n = 175)
Treatment group
“Less tight” 338 (68.6) 155 (31.4) 0.81 411 (83.9) 79 (16.1) 0.14
“Tight” 338 (69.3) 150 (30.7) 390 (80.2) 96 (19.8)
Age (years)
Mean (SD) 33.7 (5.8) 34.0 (5.8) 0.54 33.7 (5.8) 34.4 (5.9) 0.06
<35 388 (69.8) 168 (30.2) 0.50 467 (84.3) 87 (15.7) 0.04
≥35 288 (67.8) 137 (32.2) 334 (79.1) 88 (20.9)
Ethnicity
Caucasian/Asian/Other 505 (68.4) 233 (31.6) 0.57 602 (82.0) 132 (18.0) 0.94
Black/Hispanic 171 (70.4) 72 (29.6) 199 (82.2) 43 (17.8)
BMI (kg/m2)
Mean (SD) 31.0 (7.3) 31.2 (8.3) 0.81 31.5 (7.6) 29.2 (7.5) <0.001
<25 148 (64.6) 81 (35.4) 0.11 168 (73.7) 60 (26.3) <0.001
≥25 522 (70.3) 221 (29.7) 625 (84.6) 114 (15.4)
Unknown 6 (0.9) 3 (1.0) 8 (1.0) 1 (0.6)
Conceived through ART 21 (50.0) 21 (50.0) 0.007 34 (81.0) 8 (19.0) 0.86
Unknown 12 (1.8) 5 (1.6) 15 (1.9) 2 (1.1)
Gestational age at randomization (week)
Mean (SD) 24.3 (6.4) 24.5 (6.1) 0.85 24.3 (6.3) 24.7 (6.6) 0.42
<20 209 (70.1) 89 (29.9) 0.58 241 (82.0) 53 (18.0) 0.96
≥20 467 (68.4) 216 (31.6) 560 (82.1) 122 (17.9)
Nulliparous 207 (62.9) 122 (37.1) 0.004 258 (78.9) 69 (21.1) 0.07
Type of non-proteinuric hypertension
Gestational hypertension 162 (65.1) 87 (34.9) 0.13 196 (78.7) 53 (21.3) 0.11
Preexisting hypertension 514 (70.2) 218 (29.8) 605 (83.2) 122 (16.8)
Prior sBP ≥160 or dBP ≥110 mmHg in this pregnancy 83 (58.9) 58 (41.1) 0.005 114 (81.4) 26 (18.6) 0.83
Antihypertensive use at randomization 368 (65.5) 194 (34.5) 0.007 460 (82.4) 98 (17.6) 0.73
Antihypertensive type at randomization
Labetalol  other (not methyldopa) 144 (60.8) 93 (39.2) 0.001 183 (78.2) 51 (21.8) 0.06
Methyldopa  other (not labetalol) 174 (72.2) 67 (27.8) 210 (87.5) 30 (12.5)
Other 50 (59.5) 34 (40.5) 67 (79.8) 17 (20.2)
sBP within 1 week before randomization (mmHg)
Mean (SD) 139.6 (10.0) 141.1 (9.0) 0.04 140.3 (9.6) 139.4 (10.0) 0.31
<140 272 (72.3) 104 (27.7) 0.18 299 (80.2) 74 (19.8) 0.10
140–149 266 (67.2) 130 (32.8) 336 (85.3) 58 (14.7)
≥150 138 (66.0) 71 (34.0) 166 (79.4) 43 (20.6)
dBP within 1 week before randomization (mmHg)
Mean (SD) 92.2 (4.7) 92.9 (5.4) 0.04 92.3 (4.9) 93.0 (5.3) 0.12
<90 135 (71.8) 53 (28.2) 0.02 154 (83.2) 31 (16.8) 0.27
90–94 340 (70.1) 145 (29.9) 406 (83.9) 78 (16.1)
95–99 131 (71.2) 53 (28.8) 144 (78.7) 39 (21.3)
≥100 70 (56.5) 54 (43.5) 97 (78.2) 27 (21.8)
In hospital at enrolment 21 (34.4) 40 (65.6) <0.001 42 (70.0) 18 (30.0) 0.01
GDM prior to randomization 44 (69.8) 19 (30.2) 0.87 53 (84.1) 10 (15.9) 0.66
Smoking during this pregnancy 38 (60.3) 25 (39.7) 0.13 45 (71.4) 18 (28.6) 0.02
Aspirin at enrollment 178 (69.3) 79 (30.7) 0.89 221 (86.3) 35 (13.7) 0.04
Folic acid or PNV vitamin at enrolment 450 (70.5) 188 (29.5) 0.13 526 (83.0) 108 (17.0) 0.31
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Results
Of the 987 women enrolled in the CHIPS Trial, six
women were lost to follow up for the primary and sec-
ondary outcomes, leaving 981 women (99.4%) who were
included in this predictive modeling analysis. Among
these, 305 (31.1%) had primary outcomes, 175 (17.9%)
babies with birthweight <10th percentile, 334 (34.0%)
developed severe hypertension and 464 (47.3%) pree-
clampsia, 138 (14.1%) delivered at <34 weeks, and 328
(33.4%) at <37 weeks, as previously reported (10).
The baseline maternal characteristics according to the
occurrence of perinatal and maternal outcomes are exam-
ined in Tables 1 and 2, respectively. In general, in women
who suffered an adverse outcome, compared with those
who did not, a number of characteristics differed.
Although the specifics depended on the adverse outcome,
those pre-randomization characteristics most closely asso-
ciated with adverse maternal and perinatal outcomes
post-randomization were: conception through ART, prior
severe hypertension in that pregnancy, taking antihyper-
tensive therapy at time of randomization, higher sBP and
dBP at randomization, and being an inpatient at
enrolment.
The risk markers with the strongest association with
each of the outcomes, and the discrimination ability of
the model, are presented for each of the perinatal (Fig-
ure 1a,b) and maternal outcomes (Figure 1c–f); numeric
data are presented in Tables S3a,b.
The CHIPS primary perinatal outcome was more com-
mon among women who conceived by ART, were nulli-
parous or were in hospital at enrolment; the primary
outcome was less common among women who used folic
acid and/or a PNV at enrolment, were not on any antihy-
pertensive therapy, or were taking methyldopa at enrol-
ment (Figure 1a). Birthweight <10th percentile was more
common among women who were older, smokers, and
those with higher diastolic BP at enrolment, and less
common among women with higher maternal BMI or
those taking aspirin or using methyldopa as their antihy-
pertensive agent at enrolment (Figure 1b). For each of
the CHIPS primary outcome and birthweight <10th per-
centile, there was no statistical interaction between anti-
hypertensive therapy at enrolment and any variable in the
model (Table S4).
Adverse maternal outcomes were most closely related
to the woman being in hospital at enrolment and having
gestational (vs. preexisting) hypertension.
Severe hypertension was associated with “less tight” BP
control [as reported (10)], Black/Hispanic ethnicity (vs.
Caucasian/Asian/other), conception by ART, higher BP,
prior severe hypertension in the index pregnancy, and
antihypertensive therapy other than labetalol or methyl-
dopa (as previously reported)] (Figure 1c). Sensitivity
analysis revealed one interaction – increasing sBP at
enrolment had a greater impact on the likelihood of sev-
ere hypertension among women who were not on any
antihypertensive at enrolment compared with the effect
on those who were on antihypertensives (Table S4).
Preeclampsia was more common among women who
were in hospital at enrolment and had higher BP, and less
common among women taking folic acid and/or a PNV
at enrolment (Figure 1d). No significant interactions were
identified.
Very preterm delivery at <34 weeks was more common
among women who were in hospital at enrolment or had
higher BP, and less common among women were
enrolled at later gestational ages, had preexisting (vs. ges-
tational hypertension) or were taking methyldopa as their
antihypertensive agent at enrolment (as previously
reported) (17) (Figure 1e). No significant interactions
were identified.
Delivery at <37 weeks was more common among
women who were nulliparous or in hospital at enrolment,
Table 1. Continued.
Variable
Primary outcomea
pb
Birthweight <10th percentile
pbNo (n = 676) Yes (n = 305) No (n = 801) Yes (n = 175)
Unknown 1 (0.1) 0 1 (0.1) 0
PMR recruiting countryc
Low 560 (68.2) 261 (31.8) 0.28 671 (82.1) 146 (17.9) 0.91
High 116 (72.5) 44 (27.5) 130 (81.8) 29 (18.2)
ART, artificial reproductive technology; BMI, body mass index; dBP, diastolic blood pressure; Del, delivery; GDM, gestational diabetes mellitus;
Htn, hypertension; PET, preeclampsia; PMR, perinatal mortality ratio; PNV, prenatal vitamin; sBP, systolic blood pressure).
aThe primary outcome was pregnancy loss or high level neonatal care for >48 h (until primary discharge home or 28 days of life, whichever was
later) (Table S2).
bThe p-values are based on Chi-squared test, Fisher’s exact test or Wilcoxon rank sum test, as appropriate.
cLow PMR was defined as <10 perinatal deaths/1000 births and high PMR as ≥10 perinatal deaths/1000 births.
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had higher BP or prior severe hypertension in the index
pregnancy, or who were cared for in a country with a high
perinatal mortality ratio. Preterm delivery was less likely
among women with preexisting (vs. gestational) hyperten-
sion, and those either on no antihypertensive therapy or
taking methyldopa [as previously reported (17)] (Fig-
(a)
(b)
Figure 1. Risk markers associated with (a) CHIPS primary perinatal outcome, (b) birthweight <10th centile, (c) severe hypertension, (d)
preeclampsia, (e) delivery at <34 weeks and (f) delivery at <37 weeks in the final multivariable regression model. *Labetalol with or without other
(not methyldopa) as the reference category. †The primary perinatal outcome was pregnancy loss or high level neonatal care for >48 h (until
primary discharge home or 28 days of life, whichever was later).
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ure 1f). Sensitivity analysis (Table S4) revealed three inter-
actions of note: (i) higher dBP at enrolment was associated
with more preterm delivery among women on antihyper-
tensive therapy at enrolment (OR 1.07, p < 0.001) in con-
trast to those not on antihypertensives (OR = 1.01,
p = 0.85); (ii) although increased BMI (≥25 vs. <25 kg/m2)
was not associated with preterm delivery overall, these
overweight/obese women had a lower risk of preterm deliv-
ery when taking antihypertensive therapy at enrolment
(OR 0.54, p < 0.004), but a nonsignificant, increased risk
(c)
(d)
Figure 1. Continued.
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of preterm delivery when not on antihypertensive therapy
at enrolment (OR 1.26, p = 0.38); and (iii) being in hospi-
tal at enrolment was associated with preterm delivery
among women on antihypertensive therapy at enrolment
(OR 5.44, p < 0.001) but less so in women not on antihy-
pertensive therapy at enrolment (OR 1.48, p = 0.39). Inclu-
sion of the interactions did not have a meaningful effect on
the other terms in the models.
The point estimate for the AUC was <0.70 for all out-
comes except severe hypertension (0.70, 95% CI 0.67–
0.74) and delivery at <34 weeks (0.71, 95% CI 0.66–0.75)
for which AUC ROC was borderline (Figure 2). As no
(e)
(f)
Figure 1. Continued.
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model was considered potentially useful for clinical prac-
tice, no further analyses were done as regards model eval-
uation or internal validation.
Discussion
This planned secondary analysis of CHIPS Trial data sug-
gests that at the time that a pregnant woman with
chronic hypertension becomes hypertensive in the index
pregnancy, or a formerly normotensive women develops
gestational hypertension, it is not possible to use maternal
or pregnancy clinical characteristics (including the abso-
lute BP level) to predict adverse outcomes. Using models
containing all candidate predictors to start the stepwise
regression, and forcing into the model, treatment group,
antihypertensive therapy type at randomization, and BP
within 1 week before randomization, the point estimate
for the AUC was <0.70 for all outcomes (primary perina-
tal, birthweight <10th percentile, preeclampsia, and deliv-
ery at <37 weeks) except severe hypertension (AUC ROC
Figure 2. AUC ROC for prediction of major adverse pregnancy outcomes based on baseline characteristics of women enrolled in CHIPS.
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0.70, 95% CI 0.67–0.74) and delivery at <34 weeks (AUC
ROC 0.71, 95% CI 0.66–0.75) for which the AUC ROC
was borderline.
A particular strength of our study is that CHIPS was a
high-quality international RCT. Also, our analyses were
focused on whether we could identify which women were
at increased risk of adverse outcomes when antihyperten-
sive treatment decisions needed to be made for the dura-
tion of the pregnancy.
The CHIPS data set has limitations for predictive
modeling, related to focused data collection in an inter-
national pragmatic trial. CHIPS collected no information
about prior pregnancy (7,15,16,18) or family history (of
hypertension), each of which has been associated with
various adverse outcomes, ranging from preeclampsia to
preterm delivery (16,19). Another weakness of CHIPS
data is that all the candidate predictors were revealed
to the managing clinicians, who may have incorporated
those predictors into clinical decision-making. This
means that prediction of adverse outcomes for each item
is susceptible to “treatment paradox,” meaning relation-
ships between candidate predictors and outcomes may be
confounded when the clinician uses these predictors in
decision-making. This treatment paradox may mask an
association between the variable and outcome, or create
an association when none actually exists. For example, a
variable that may be predictive of severe hypertension
may not be identified as such if the presence of that
variable leads to antihypertensive therapy that avoids the
severe hypertension and its complications; this may be
why BP level was not predictive of adverse maternal out-
come in the PIERS model of prognosis among women
hospitalized with preeclampsia (3). Another example of
this is the lack of a demonstrated association between
corticosteroids and reduced neonatal mortality and mor-
bidity in data of babies admitted to neonatal intensive
care in the Canadian Neonatal Network (20). Many
other predictive databases suffer from the same weakness,
which should indicate the need for caution in interpret-
ing predictive models from data sets in which clinicians
know some or all of the variables analyzed. Although this
issue has not been adequately addressed to date, it
should be noted that our model used baseline character-
istics that clinicians will know, such as demographics
and baseline BP, as opposed to biomarkers or investiga-
tional ultrasonographic results, which can be masked
from clinicians.
Although a multivariable model that could predict
adverse outcome was not identified, in univariable analy-
ses, baseline factors significantly associated with adverse
outcomes were consistent with published literature that
has included adverse prognostic factors of older maternal
age, conception by ART, nulliparity, smoking, no use of
low-dose aspirin, earlier gestational age (at diagnosis with
hypertension), higher BP, severe hypertension in that
pregnancy, use of antihypertensive therapy, and higher
serum uric acid (9,11–13). Use of antihypertensive ther-
apy at randomization magnified the risk associated with
higher BP for progression to severe hypertension and pre-
term delivery, and being in hospital at enrolment for pre-
term delivery. Interestingly, use of antihypertensive
therapy was associated with a decrease in preterm delivery
among overweight/obese women, suggesting that clini-
cians time delivery differently in these women.
There were a few other findings of specific note.
First, women with high BMI less frequently had babies
with birthweight <10th percentile, likely representing the
interplay between hypertension-related fetal growth
restriction and obesity-related macrosomia.
Also, the association of preexisting hypertension with
better outcomes compared with gestational hypertension,
was related to the fact that gestational age at presentation
had to be <34 weeks in CHIPS, so these women with ges-
tational hypertension were a high-risk subgroup of hyper-
tensive pregnant women with a higher risk of progression
to preeclampsia (21–25).
In addition, analyses of the CHIPS data set showing
better prognosis with methyldopa (vs. labetalol) antihy-
pertensive therapy have been reported and discussed pre-
viously (17). In brief, women treated with methyldopa
(vs. labetalol) may have had better outcomes, particularly
women with preexisting hypertension, accounting for
centre (and thereby, differences in practice) and baseline
participant differences; however, these non-randomized
comparisons may be subject to residual confounding.
With regard to preventative therapy, aspirin use in this
high-risk cohort of women was low. Although 75% of
women in CHIPS had preexisting hypertension, only
~25% of women were prescribed aspirin at enrolment at
an average gestational age of 24 weeks (10). This under-
use of aspirin is not in keeping with recommendations to
use it for preeclampsia prevention in women at increased
risk (such as those with preexisting hypertension) (26–31)
with no guideline recommending against it. Aspirin was
not associated with a reduction in preeclampsia in this
cohort but CHIPS was underpowered to find the small
effect that could be anticipated. Also, taking a folate-
containing PNV was associated with lower rates of the
primary outcome and preeclampsia; the Folic Acid Clini-
cal Trial (NCT01355159) is examining whether high-dose
folic acid decreases preeclampsia.
Finally, preterm delivery was increased in countries
with a high perinatal mortality ratio, possibly related to
general factors associated with preterm birth, such as
poor nutrition or socioeconomic status; these were not
measured in CHIPS.
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In conclusion, it was not possible to identify which
women were at increased risk of perinatal or maternal
adverse outcomes based on maternal and current preg-
nancy clinical characteristics at the time of CHIPS Trial
enrolment. All such women must be followed closely and
counseled accordingly.
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